Currus Biologics announces FDA IND clearance for Phase 1 trial of CUR-001 in mesothelin-positive advanced refractory solid tumours

Phase 1approvedCUR-001Positive

AI Analysis

Summary

Currus Biologics announced FDA IND clearance to initiate a Phase 1 trial of CUR-001, a mesothelin-targeting therapy, in patients with advanced refractory solid tumours.

Clinical Trial Data

Phase

Phase 1

Outcome Details

FDA IND clearance granted

Importance:5/10

Sentiment:

0.70

IND clearanceoncologymesothelinsolid tumoursimmunotherapy

Related Companies

$SLDB

Read the original article

Published by GlobeNewswire Clinical Studies on September 28, 2026 10:00 PM

Read Original